Evan Y. Yu, MD, discusses the safety data from the phase 3 PEACE-3 study of enzalutamide (ENZA) combined with radium-223 (Ra-223) for androgen receptor pathway inhibitor (ARPI)–naive metastatic ...
Evan Y. Yu, MD, discusses the key efficacy findings from the PEACE-3 study, which assessed the combination of enzalutamide (ENZA) and radium-223 (Ra-223) in androgen receptor pathway inhibitor ...
Journal of Nuclear Medicine February 2025, jnumed.124.268340; DOI: https://doi.org/10.2967/jnumed.124.268340 ...
Xtandi is advancing treatment for late-stage prostate cancer, enhancing longevity and wellness. Xtandi targets prostate cancer cases deemed high-risk due to aggressive disease characteristics, such as ...
We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...
Background: Abiraterone and enzalutamide are widely used as first-line treatment for metastatic castration-resistant prostate cancer (mCRPC); however, their efficacy in mCRPC has been inconsistently ...
Objective: To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of ...
Prostate cancer drug Xtandi has been given FDA approval for use as a first line treatment for metastatic castration-resistant prostate cancer (CRPC). The new approval allows Astellas and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback